Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Johnson & Johnson said new exploratory biomarker analyses from its Phase 2 DAHLIAS study of nipocalimab in adults with moderate-to-severe Sjögren’s disease found higher autoantibody/IgG levels were linked to higher clinical response rates. In the autoantibody-high subgroup, response was 62.5% vs 51.9% overall. J&J said results build on prior ClinESSDAI improvements vs placebo and will be presented at EULAR 2026.
The update strengthens the clinical narrative and patient-subgroup signal for nipocalimab ahead of Phase 3 DAFFODIL, supporting risk-on sentiment for the program.
Johnson & Johnson reports new Phase 2 biomarker analyses for nipocalimab in Sjögren’s, showing higher response in autoantibody-high patients.
Moderate positive bias for JNJ biotech sentiment; likely limited immediate impact unless the market was underweight the Sjögren’s readout.
Background
Nipocalimab is an investigational immunoselective FcRn blocker in Sjögren’s; J&J is running Phase 3 DAFFODIL after earlier Phase 2 results and multiple FDA designations (Fast Track/Breakthrough).
Why it matters
The article adds exploratory biomarker analysis from Phase 2 DAHLIAS, linking elevated autoantibody/IgG levels to higher clinical response rates, which can refine patient selection and strengthen the mechanistic story for Phase 3.
Market relevance
A strengthened subgroup response signal (autoantibody-high) can improve investor confidence in the program’s differentiation, but it is not a new primary endpoint readout.
Market effects
Reinforces the broader FcRn-blocker autoantibody-reduction thesis in autoimmune disease, potentially improving perceived odds for similar programs.
Primarily US pharma sentiment; EULAR presentation may drive incremental European biotech attention.
Could modestly affect global autoimmune/biomarker-driven development expectations for FcRn blockers.
Alternative perspectives
Exploratory subgroup/bio-marker analyses may not translate into durable efficacy or regulatory-grade endpoints, so the market may discount the incremental signal.
Key risk remains whether Phase 3 DAFFODIL confirms clinically meaningful benefit in the broader population and whether safety/tolerability holds at scale.
Key entities
- drugNipocalimab
Investigational immunoselective FcRn blocker targeting pathogenic IgG autoantibodies in Sjögren’s disease.
- clinical_trialDAHLIAS (NCT04968912)
Phase 2 randomized, placebo-controlled dose-ranging study in moderate-to-severe primary Sjögren’s disease.
- clinical_trialDAFFODIL
Ongoing Phase 3 study referenced as the next step for nipocalimab in Sjögren’s.
- eventEULAR Congress 2026
Congress where the new analyses are planned for oral presentation.
